Last reviewed · How we verify
Aureotan (aurothioglucose)
At a glance
| Generic name | aurothioglucose |
|---|---|
| Drug class | aurothioglucose |
| Target | 5-hydroxytryptamine receptor 3A |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
- Juvenile rheumatoid arthritis
- Rheumatoid arthritis
Common side effects
Key clinical trials
- Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer (PHASE1,PHASE2)
- Multi Interventional Approaches to Mitigate HIV Reservoirs Aiming the Sustained HIV Remission Without Antiretrovirals (PHASE2)
- Auranofin and Sirolimus in Treating Participants With Ovarian Cancer (PHASE2)
- Auranofin for Giardia Protozoa (PHASE2)
- A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma (PHASE1,PHASE2)
- Multi Interventional Study Exploring HIV-1 Residual Replication: a Step Towards HIV-1 Eradication and Sterilizing Cure (NA)
- Auranofin in Treating Patients With Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (EARLY_PHASE1)
- Auranofin in Decreasing Pain in Patients With Paclitaxel-Induced Pain Syndrome (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aureotan CI brief — competitive landscape report
- Aureotan updates RSS · CI watch RSS
- portfolio CI